Confidential results No doctor visit required Results in 1-3 days 4,500+ locations
Infectious Disease

Epstein-Barr Virus (EBV) Panel

Comprehensive antibody panel to determine current, past, or recent Epstein-Barr virus infection status and distinguish between acute and chronic EBV infections.


Order this test

LevelPanel has no business or affiliate relationship with Quest or LabCorp. These links are provided as a public service.

Lab testing services linked from this site are not available to residents of Alaska, Arizona, or Hawaii, unless otherwise noted on the lab's own website.

This publication is not intended to solicit the purchase of laboratory testing from any individual consumer.

Blood
HIPAA CompliantCLIA-Certified LabsPhysician-AuthorizedBank-Level Encryption

What this test measures

This panel measures four distinct antibodies that the immune system produces at different stages of Epstein-Barr virus (EBV) infection, allowing healthcare providers to determine not only whether exposure has occurred but also when. EBV is the most common cause of infectious mononucleosis and establishes a lifelong latent infection after the initial illness resolves.

The four antibodies follow a predictable timeline. Viral capsid antigen (VCA) IgM appears early in infection and typically fades within four to six weeks, making it the primary marker of acute infection. VCA IgG also appears during the acute phase, peaks within two to four weeks of symptom onset, and then persists for life as a marker of past exposure. Early antigen (EA) IgG emerges during active infection and generally declines to undetectable levels within three to six months. EBV nuclear antigen (EBNA) IgG develops slowly, appearing two to four months after symptom onset, and persists indefinitely. The specific combination of positive and negative results across these four markers allows healthcare providers to classify the infection as acute, recent, past, or reactivated.

What's included

EBV VCA IgM
EBV VCA IgG
EBV Nuclear Antigen IgG
EBV Early Antigen IgG

Who should consider this test

You might consider this test if you are experiencing any of the following:

  • Individuals experiencing symptoms of infectious mononucleosis, including persistent fatigue, fever, sore throat, swollen lymph nodes, and body aches, particularly when a standard mono test is negative.
  • People who have been exposed to someone with confirmed EBV infection or infectious mononucleosis and want to determine their infection status or susceptibility.
  • Patients with unexplained prolonged fatigue or flu-like symptoms that may be related to EBV infection, especially when other causes have been ruled out.
  • Healthcare workers, teachers, or others in close contact environments who need to understand their EBV status for occupational health purposes.
  • Individuals with compromised immune systems who may be at increased risk for EBV-related complications or reactivation of the virus.
  • Pregnant women experiencing viral-like symptoms to help distinguish EBV from other infections that may affect pregnancy outcomes.
  • People considering or undergoing organ transplantation, as EBV status can be important for determining infection risk and treatment protocols.

What to expect

Preparation

No special preparation is needed for this test. Individuals should inform their healthcare provider about any medications they are taking, though most medications do not interfere with EBV antibody testing.

Sample Type

A healthcare professional will draw a small blood sample from a vein in the arm using a sterile needle. The procedure typically takes just a few minutes and causes minimal discomfort.

Collection

At the laboratory or clinic, patients will have their identity verified and a small amount of blood drawn into collection tubes. The sample will be processed to separate serum for antibody testing.

Turnaround

Results are typically available within 1-3 business days after the laboratory receives the sample, allowing for prompt evaluation of EBV infection status.

Understanding your results

Results are reported as positive or negative (or as titers) for each of the four antibody markers. The diagnostic power lies in the pattern. For example, positive VCA IgM with negative EBNA IgG strongly suggests a primary acute infection, while positive VCA IgG and EBNA IgG with negative VCA IgM indicates past infection with established immunity. Positive EA IgG alongside VCA IgM may indicate active or recent infection. Healthcare providers read the four results together, in combination with symptoms and clinical history, to determine the stage of EBV infection and whether the current illness is attributable to the virus.

PopulationReference RangeNotes
AdultsNegative/Positive for each antibody componentResults are reported as negative, equivocal, or positive for each of the four antibody types tested

Reference ranges may vary by laboratory and individual factors. Results should be interpreted by a healthcare provider in the context of your overall health.

What does a “Low” result mean?

Negative results for all EBV antibodies typically indicate that an individual has not been exposed to the Epstein-Barr virus and remains susceptible to infection. People are considered susceptible to EBV infection if they do not have antibodies to the VCA. However, in rare cases, people with active EBV infections may not have detectable EBV-specific antibodies. Negative results should be interpreted in the context of symptoms and clinical presentation, as resolution of illness may occur before diagnostic antibody levels appear.

What does a “High” result mean?

Positive results for different antibody combinations may indicate various infection stages. A primary EBV infection is suggested when anti-VCA IgM is present but EBNA antibody is absent. The presence of antibodies to both VCA and EBNA suggests past infection from several months to years earlier. Detection of early antigen antibody is often a sign of active infection, though about 20% of healthy people may have antibodies against early antigen for years. The specific combination of positive antibodies helps determine whether someone has a current, recent, or past EBV infection.

Privacy & confidentiality

All EBV panel results are completely confidential and protected under HIPAA regulations. Results are not shared with insurance companies, will not appear on insurance explanation of benefits, and are not automatically added to your medical records unless you choose to share them with your healthcare provider.

Frequently asked questions

Related tests

Related conditions

Last reviewed: April 2026

CPT Code: 86663, 86664, 86665, 86665

This test may not be available in: NY, NJ, RI

This page is for informational purposes only and does not constitute medical advice. Always consult with a healthcare provider regarding any health concerns. LevelPanel does not diagnose, treat, or prescribe.

This page is intentionally kept stable and machine-readable so that researchers, clinicians, and AI systems can rely on it as a reference. See our Citation Policy.